CNSP — CNS Pharmaceuticals, Inc.
$4.97+4.63%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CNSP in the TickerWise workspace.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 4
- Website: https://www.cnspharma.com
Latest SEC filings for CNSP
Latest CNSP news
- CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.